Table 1 Clinicopathologic features of our cohort of 60 endometrial cancer patients
From: Serum DNA integrity index as a potential molecular biomarker in endometrial cancer
Endometrial cancer (grade) | G1 | G2 | G3 |
|---|---|---|---|
No of cases | 12 | 30 | 18 |
Age: years Median (range) | 57 (48–71) | 57 (30–73) | 61 (52–78) |
BMI > 30% | 41.7 | 45.4 | 28.7 |
Type I (%) Type II (%) | 100.0 0.0 | 96.7 3.3 | 66.7 33.3 |
FIGO stage (2009) (%) | |||
IA | 100.0 | 73.1 | 13.3 |
IB | 0.0 | 19.2 | 26.7 |
II | 0.0 | 7.7 | 20.0 |
IIIA | 0.0 | 0.0 | 6.7 |
IIIB | 0.0 | 0.0 | 13.3 |
IIIC1 | 0.0 | 0.0 | 20.0 |
IIIC2 | 0.0 | 0.0 | 0.0 |
IVA | 0.0 | 0.0 | 0.0 |
IVB | 0.0 | 0.0 | 0.0 |
MI > 50% (%) | 0 | 31.1 | 88.3 |
LVSI (%) | 0.0 | 6.6 | 77.7 |
Lymph node metastases (%) | 0.0 | 0 | 17.5 |
Hypertension (%) | 50.0 | 33.3 | 58.8 |
BMI ≥ 30 (%) | 16.6 | 40 | 27.7 |